A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions.
Twenty seven adults and 20 children with previously diagnosed stable asthma, using a salbutamol pressurized metered dose inhaler (P-MDI) and living in Cairns, Townsville and Southport, Queensland, Australia participated in a randomized, open-label cross-over comparison of terbutaline administered via Turbuhaler and salbutamol administered via P-MDI. The aim of the study was to compare the clinical effectiveness and patient acceptance of the two treatments in hot, humid regions. Terbutaline was administered via Turbuhaler and salbutamol via P-MDI on at least two occasions per day during each four week treatment period. Spirometry was performed at the start of the study, after the two week run-in and at the end of each treatment period. Patients used diary cards to record morning and evening peak expiratory flows, daily symptom scores and daily intake of beta 2 agonist medication. At the end of the study, patients answered a treatment preference question. Forty six patients completed the study. No statistically significant differences were observed between the two treatments in peak expiratory flow, change in morning peak expiratory flow pre- and post-beta-agonist, daily symptom scores, diurnal variability and spirometry. Forty four percent of patients preferred the terbutaline Turbuhaler and 39% preferred salbutamol P-MDI. Both agents were similarly tolerated. Terbutaline delivered by Turbuhaler is as clinically effective as salbutamol delivered by P-MDI in patients with asthma living in hot, humid regions.
Lindsay
D A
DA
Astra Pharmaceuticals Pty. Ltd, North Ryde, NSW, Australia.
Russell
N L
NL
Thompson
J E
JE
Warnock
T H
TH
Shellshear
I D
ID
Buchanan
P R
PR
D000336:Aerosols; D000420:Albuterol / Q000008:administration & dosage* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D005260:Female; D006358:Hot Temperature; D006801:Humans; D006813:Humidity; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D010342:Patient Acceptance of Health Care; D011793:Queensland; D013726:Terbutaline / Q000008:administration & dosage* / Q000627:therapeutic use
D000336:Aerosols; D013726:Terbutaline; D000420:Albuterol